Physician profile
Jeffrey A Klein
NPI 1972699304
$2,581.75
in general payments reported to CMS, 2019-2025
22 companies · $682 in 2025
The $682 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $189 · 2021: $307 · 2022: $157 · 2023: $539 · 2024: $312 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $924 · Debt Forgiveness: $536 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.26 |
| Debt Forgiveness | $536.26 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $616.62 | 2019-2025 | Bf-Rhodoled, Xepi, Bf-Rhodoled |
| Abbvie INC. | $447.04 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $318.86 | 2019-2025 | |
| Pfizer INC. | $224.21 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $151.36 | 2019-2024 | Winlevi, Absorica Ld |
| Genentech USA, INC. | $115.86 | 2019-2021 | |
| Janssen Biotech, INC. | $108.63 | 2023 | Tremfya, Stelara, Remicade |
| Leo Pharma INC. | $100.07 | 2019-2020 | |
| Revance Therapeutics, INC. | $94.99 | 2024 | Daxxify |
| Mimedx Group, INC. | $61.47 | 2024-2025 | |
| Strata Skin Sciences, INC. | $51.24 | 2025 | Xtrac |
| Genzyme Corporation | $51.03 | 2021-2025 | |
| Glaxosmithkline, LLC. | $43.90 | 2019-2020 | |
| Dermira, INC. | $30.82 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.11 | 2023 | Libtayo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $25.66 | 2024 | Cygnus Dual |
| Amgen INC. | $22.65 | 2023 | Otezla |
| Sientra, INC. | $20.74 | 2020 | |
| Galderma Laboratories, L.P. | $17.91 | 2021 | |
| Dermavant Sciences, INC. | $17.86 | 2024 | Vtama |
| Apyx Medical Corporation | $16.70 | 2020 | |
| Allergan, INC. | $16.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.